{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T10:10:19Z","timestamp":1768126219503,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1097\/maj.0b013e3181ff8eeb","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T08:46:02Z","timestamp":1294908362000},"page":"394-398","source":"Crossref","is-referenced-by-count":27,"title":["Clinical Improvement in Psoriasis With Treatment of Associated Hyperlipidemia"],"prefix":"10.1016","volume":"341","author":[{"given":"Ramin","family":"Ghazizadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Tosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ghazizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0005","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features","volume":"64","author":"Langley","year":"2005","journal-title":"and quality of life. Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/sj.jid.5700223","article-title":"Assessing the impact of psoriasis and the relevance of qualitative research","volume":"126","author":"Jobling","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clindermatol.2007.08.006","article-title":"Comorbidities in psoriasis","volume":"25","author":"Christophers","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2133.2004.06035.x","article-title":"Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased","volume":"151","author":"Jacobson","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clindermatol.2009.03.001","article-title":"Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2133.2008.08707.x","article-title":"Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis","volume":"159","author":"Kaye","year":"2008","journal-title":"Bt J Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0040","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5021\/ad.2010.22.3.300","article-title":"Association between psoriasis and cardiovascular risk factors in Korean patients","volume":"22","author":"Choi","year":"2010","journal-title":"Ann Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0050","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00109-003-0460-9","article-title":"A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses","volume":"81","author":"Ghoreschl","year":"2003","journal-title":"J Mol Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0167-5699(89)90039-X","article-title":"The CD2-LFA-3 and LFA-1- ICAM pathways: relevance to T-cell recognition","volume":"10","author":"Makgoba","year":"1989","journal-title":"Immunol Today"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0060","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","article-title":"Involvement of IL-17F via the induction of IL-6 in psoriasis","volume":"302","author":"Fujishima","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0070","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0509736102","article-title":"Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)","volume":"102","author":"Lowes","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0075","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Michelle","year":"2007","journal-title":"Nature"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0080","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple pro-inflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J Immunol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0085","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0090","doi-asserted-by":"crossref","first-page":"21751","DOI":"10.1074\/jbc.M212662200","article-title":"Histamine antagonizes tumor necrosis factor (TNF) signalling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0095","first-page":"145","article-title":"The tumour necrosis factor family of receptors\/ligands in the serum of patients with rheumatoid arthritis","volume":"9","author":"Robak","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/BF01957501","article-title":"Definition of a new score for severity of generalized Neisseria meningitidis infection","volume":"154","author":"Nurnberger","year":"1995","journal-title":"Eur J Pediatr"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(87)91728-4","article-title":"Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease","volume":"1","author":"Waage","year":"1987","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0110","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0140-6736(90)92827-5","article-title":"TNF concentration in fatal cerebral, non-fatal cerebral and uncomplicated Plasmodium falciparum malaria","volume":"336","author":"Kwiatkowski","year":"1990","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ncb1086","article-title":"A physical and functional map of the human TNF \u03b1\/NF-\u03baB signal transduction pathway","volume":"6","author":"Bouwmeester","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0120","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"31","key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0125","first-page":"e1","article-title":"A randomized com parison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2008.08628.x","article-title":"Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis","volume":"159","author":"Strober","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0135","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1468-3083.2009.03527.x","article-title":"C-reactive protein and leukocyte activation in psoriasis vulgaris according to severity and therapy","volume":"24","author":"Coimbra","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosissup.2006.01.005","article-title":"Statins: potential new indications in inflammatory conditions","volume":"7","author":"Endres","year":"2006","journal-title":"Atheroscler Suppl"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0150","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/eji.200838863","article-title":"Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation","volume":"39","author":"Raemer","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2006.08.003","article-title":"Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cyto-skeleton of activated endothelial cells","volume":"548","author":"Pozo","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/bja\/ael358","article-title":"Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide","volume":"98","author":"McGown","year":"2007","journal-title":"Br J Anaesth"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0165","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaut.2005.06.005","article-title":"Effect of atorvastatin on the Th1\/Th2 polarization of ongoing experimental autoimmune myocarditis in lewis rats","volume":"25","author":"Liu","year":"2005","journal-title":"J Autoimmun"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardfail.2008.10.001","article-title":"Atorvastatin modulates Th1\/Th2 response in patients with chronic heart failure","volume":"15","author":"Cheng","year":"2009","journal-title":"J Card Fail"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrn1652","article-title":"Statins\u2014a cure-all for the brain?","volume":"6","author":"Menge","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopha.2009.03.003","article-title":"Atorvastatin inhibits inflammatory angiogenesis in mice through downregulation of VEGF, TNF-alpha and TGF-beta-1","volume":"64","author":"Araujo","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0185","article-title":"Statins potently reduce the cytokine-mediated IL-6 release in SMC\/MNC cocultures","author":"Loppnow","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MAJ.0b013e3181e2b353","article-title":"Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction","volume":"340","author":"Xu","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5551\/jat.2956","article-title":"Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes","volume":"17","author":"Mandosi","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0200","first-page":"37","article-title":"Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension., et al","volume":"50","author":"Vasiuk","year":"2010","journal-title":"Kardiologiia"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0205","article-title":"Statins as newly recognized type of immunomodulator","volume":"1399\u2013402","author":"Kwak","year":"2000","journal-title":"Nature"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0210","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nm0405-365","article-title":"Statins and control of MHC2TA gene transcription","volume":"11","author":"Kuipers","year":"2005","journal-title":"Nat Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJMe048326","article-title":"Statins for atherosclerosis\u2014as good as it gets?","volume":"352","author":"Ehrenstein","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00414-0","article-title":"Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin","volume":"269","author":"Stanislaus","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0225","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0230","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20021425","article-title":"Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin","volume":"197","author":"Aktas","year":"2003","journal-title":"J Exp Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0235","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00415-003-1070-8","article-title":"Therapeutic potential of lovastatin in multiple sclerosis","volume":"250","author":"Sena","year":"2003","journal-title":"J Neurol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0240","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","article-title":"Oral simvastatin treatment in relapsing-remitting multiple sclerosis","volume":"363","author":"Vollmer","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0245","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0250","first-page":"23","article-title":"A low-fat diet supplemented with dietary fish oil (Max-EPA) results in improvement of psoriasis and in formation of leukotriene B 5","volume":"69","author":"Kragballe","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0255","first-page":"41","article-title":"The role of the low energy diet in psoriasis vulgaris treatment","volume":"27","author":"Rucevic","year":"2003","journal-title":"Coll Antropol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0260","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2340\/0001555563397403","article-title":"A fasting and vegetarian diet treatment trial on chronic inflammatory disorders","volume":"63","author":"Lithell","year":"1983","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0265","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-X","article-title":"Disease concomitance in psoriasis","volume":"32","author":"Henseler","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2133.1996.tb07846.x","article-title":"Dietary factors and the risk of psoriasis. Results of an Italian case-control study","volume":"134","author":"Naldi","year":"1996","journal-title":"Br J Dermatol"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0275","first-page":"57","article-title":"Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids","volume":"37","author":"Grimble","year":"1998","journal-title":"Z Ernahrungswiss"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1529-8019.2010.01309.x","article-title":"Psoriasis and body mass index","volume":"23","author":"Hercogov\u00e1","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.0022-202X.2005.23681.x","article-title":"Cigarette smoking, body mass index and stressful life events as risk factors for psoriasis: result from an Italian case-control study","volume":"125","author":"Naldi","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0290","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, waist circumference, weight change, and the risk of psoriasis in women","volume":"167","author":"Setty","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0295","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaad.2007.05.040","article-title":"Efficacy of simvastatin in plaque psoriasis: a pilot study","volume":"57","author":"Shirinsky","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000182258","article-title":"Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey","volume":"218","author":"Wolkenstein","year":"2009","journal-title":"Dermatology"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0305","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0310","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0906-6705.2004.00208.x","article-title":"Statins: novel additions to the dermatologic arsenal?","volume":"13","author":"Namazi","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1097\/MAJ.0b013e3181ff8eeb_bb0315","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915312969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T18:03:22Z","timestamp":1740852202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915312969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0002962915312969"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181ff8eeb","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}